Metabolic & Cardiometabolic

PCSK9 inhibitors (evolocumab, alirocumab) decreases LDL cholesterol (~50-60%)

In plain terms: Do PCSK9 inhibitors like evolocumab and alirocumab substantially lower LDL cholesterol?

Strong support Metabolic & Cardiometabolic 🔬 Includes disconfirming

RefutedContestedStrong support

consensus score 1.00

Yes, unequivocally — monoclonal PCSK9 antibodies cut LDL cholesterol by roughly 50-60% on top of statins, one of the most reproducible drug effects in lipidology.

📅 Last reviewed: 2026-07-14 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

11 support 0 contradict 1 tested null 0 mixed · 12 sources, 11 independent groups · 2 superseded — pooled inside a review, counted once

Cochrane agrees with us see how our grade compares ▾

Cochrane review 2020 · high (clinical endpoints for evolocumab and alirocumab) Agrees with our grade

“PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease (CD011748.pub3). 'The evidence for the clinical endpoint effects of evolocumab and alirocumab were graded as high. There is a strong evidence base to prescribe PCSK9 monoclonal antibodies...'”

Why we agree: we reached the same direction independently, from our own appraisal of 12 sources. Two methods landing in the same place is a stronger signal than either alone.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (14)

Source	Grade	Stance	Quality	Finding
Robinson 2015 (ODYSSEY LONG TERM) venue: N Engl J Med · N Engl J Med	RCT	supports	high	ODYSSEY LONG TERM: alirocumab 150mg in 2,341 high-risk patients lowered LDL 62% vs placebo at week 24, sustained over 78 weeks.
Koren 2014 (MENDEL-2) venue: J Am Coll Cardiol · J Am Coll Cardiol	RCT	supports	high	MENDEL-2: evolocumab monotherapy (no statin) lowered LDL 55-57% vs placebo and 38-40% vs ezetimibe in 614 low-risk patients.
Toth 2017 · J Am Heart Assoc	meta-analysis	supports	high	Network meta-analysis: evolocumab gave the largest LDL reductions (~54-75% by background) versus ezetimibe and placebo across therapy combinations.
Blais JE 2026 · JACC Adv	observational	tested-null	moderate	Systematic review/meta-analysis (94 studies, n=75,902) of PCSK9 inhibitor adherence in clinical practice; presupposes established LDL-C-lowering efficacy while focusing on real-world adherence rates (91.7% initiation, 81.8% persis
Sabatine 2015 (OSLER) venue: N Engl J Med · N Engl J Med	RCT	supports	high	OSLER open-label extensions: evolocumab lowered LDL 61% (median 120→48 mg/dL) in 4,465 patients; consistent with phase 2/3 program.
Schwartz 2018 (ODYSSEY OUTCOMES) venue: N Engl J Med · N Engl J Med	RCT	supports	high	ODYSSEY OUTCOMES: alirocumab in 18,924 post-ACS patients on statins lowered LDL ~55% at 4 months and reduced major CV events (HR 0.85).
Raal 2015 (RUTHERFORD-2) venue: Lancet · Lancet	RCT	supports	high	RUTHERFORD-2: evolocumab in 331 heterozygous FH patients on statins lowered LDL 59-66% vs placebo — effective even in genetic hypercholesterolemia.
Guedeney 2019 · Eur Heart J	meta-analysis	supports	high	Meta-analysis of alirocumab and evolocumab RCTs showed large LDL-C reductions with corresponding decreases in cardiovascular events.
Sabatine 2017 (FOURIER) venue: N Engl J Med · N Engl J Med	RCT	supports	high	FOURIER: evolocumab in 27,564 statin-treated ASCVD patients lowered LDL 59% (median 92→30 mg/dL) and cut CV events 15%; definitive large-scale LDL effect.
Arnaboldi L 2026 · Eur Heart J Suppl	observational	supports	moderate	Phase III trials (CORALreef-Lipids, CORALreef-HeFH) of oral PCSK9 inhibitor enlicitide confirmed LDL-C reductions of 55-60%, comparable to monoclonal antibodies; AZD0780 reduced LDL-C up to 50%.
Blom 2014 (DESCARTES) venue: N Engl J Med · N Engl J Med	RCT	supports	high	DESCARTES: 52-week evolocumab lowered LDL ~57% vs placebo in 901 patients on background therapy — durable year-long reduction. ↩ SUPERSEDED — pooled in the review above, counted once
Navarese 2015 · Ann Intern Med	meta-analysis	supports	high	Meta-analysis of 24 trials (10,159 patients): PCSK9 antibodies lowered LDL ~47% and, in pooled data, reduced all-cause mortality — independent confirmation.
Burnett 2025 · J Cardiovasc Pharmacol	meta-analysis	supports	moderate	Updated network meta-analysis of 20 trials confirms PCSK9 monoclonal antibodies produce among the largest LDL-C reductions of non-statin therapies.
Robinson 2014 (LAPLACE-2) venue: JAMA · JAMA	RCT	supports	high	LAPLACE-2: evolocumab added to moderate/high-intensity statins lowered LDL 63-75% vs placebo across 2,067 patients; beat ezetimibe add-on. ↩ SUPERSEDED — pooled in the review above, counted once

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.